Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on CN114057717B. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel quinoline-substituted bisoxazoline ligand enables high enantioselectivity in trifluoromethylation. Offers scalable synthesis and cost-effective supply chain solutions for pharmaceutical intermediates.
Patent CN114057717B reveals novel ligand synthesis enhancing enantioselectivity. Delivers substantial cost reduction in pharmaceutical intermediates manufacturing and supply chain reliability.
Novel quinoline-substituted ligand enables high ee asymmetric trifluoromethylation. Cost-effective synthesis for pharmaceutical intermediate manufacturing supply chain.